MedTrace Logo

Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study

NCT02486445 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 625

Last updated 2019-01-23

No results posted yet for this study

Summary

This prospective outcome study is designed to assess the safety of rivaroxaban in the pre-diagnosis phase of DVT.

Conditions

  • Deep Venous Thrombosis

Interventions

DRUG

Rivaroxaban

Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)

Sponsors & Collaborators

  • Ostfold Hospital Trust

    lead OTHER

Principal Investigators

  • Waleed Ghanima, PhD · Ostfold Hospital Trust

  • Nezar Raouf · Ostfold Hopital Trust

  • Kristin Utne · Ostfold Hospital Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-11-30
Completion
2018-12-30

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02486445 on ClinicalTrials.gov